Holen Sie sich die Stockscreener-App
106.09
0.04%
0.04
Handel nachbörslich:
105.94
-0.15
-0.14%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
The Truth About Abbott Laboratories: Is This ‘Boring’ Stock Actually a Secret Power Play? - AD HOC NEWS
Top Analyst Reports for Applied Materials, Linde & Abbott - TradingView
Abbott Laboratories Options Spot-On: On January 29th, 154.5K Contracts Were Traded, With 195.89K Open Interest - 富途牛牛
Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries - TechStock²
5 Insightful Analyst Questions From Abbott Laboratories's Q4 Earnings Call - Finviz
Freedom Capital Markets upgrades Abbott Labs stock rating to Buy on Exact Sciences deal - Investing.com
Down 16% In Last 12 Months, Will Abbott Laboratories Stock Recover In 2027? - TIKR.com
Abbott CEO Signals Confidence with Major Share Purchase - AD HOC NEWS
5 Insightful Analyst Questions From Abbott Laboratories’s Q4 Earnings Call - Yahoo Finance
Abbott stock slides after CEO’s $2 million buy hits SEC filing — what investors watch next - TechStock²
How New Price Targets Are Shaping The Evolving Story For Abbott Laboratories (ABT) - Yahoo Finance
Abbott Laboratories stock price slides as Argus cuts target and CEO Ford discloses share buy - TechStock²
Babies Are Getting Sick From Formula That Mimics Mother’s Milk - Bloomberg
Here’s Why Abbott Stock Could Deliver 10% Upside in 2026 After a 15% Decline Last Year - TIKR.com
Abbott stock fell the most in 23 years after earnings. The CEO bought $2 million of shares - MSN
Abbot (ABT) is a High Quality Company, Says Jim Cramer - Insider Monkey
Abbott Stock Fell the Most in 23 Years After Earnings. The CEO Bought $2 Million of Shares. - Barron's
Abbott Laboratories Stock: Join the Rally at a 19% Discount - Trefis
Abbott Laboratories Stock Now 19% Cheaper, Time To Buy - Trefis
What To Expect From Stryker’s (SYK) Q4 Earnings - TradingView
Is Abbott (ABT) Insider Buying Offsetting Concerns Around Nutrition and Diagnostics Earnings Pressure? - simplywall.st
Abbott Laboratories (NYSE:ABT) Finds Support After Recent S&P 500 Decline - Kalkine Media
Abbott: Study shows neuromod systems greatly reduce pain-related healthcare visits - MassDevice
Abbott executive who led TAVR, Tendyne divisions announces exit - Cardiovascular Business
Transcatheter Embolization and Occlusion Devices Market Size to be Valued at USD 11.53 Billion by 2033, Driven by Rising Oncology and Neurovascular Interventions – SNS Insider - GlobeNewswire Inc.
Lbp Am Sa Boosts Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Optimism around Abbott Laboratories (NYSE:ABT) delivering new earnings growth may be shrinking as stock declines 11% this past week - Yahoo Finance
ABT.SW Abbott Laboratories (SIX) CHF100 27 Jan 2026 volume spike: watch momentum - Meyka
Top Executive Makes Bold Move With Major Abbott Laboratories Stock Purchase - TipRanks
Abbott Reworks Nutrition While Targeting Cancer Diagnostics With Exact Sciences Deal - simplywall.st
Ill. Judge Trims False Ad Suit Over Abbott Formula - Law360
Evercore ISI says Abbott’s (ABT) core growth drivers are still intact - MSN
Abbott Laboratories (ABT) Rebounds After Recent Losses - GuruFocus
Abbott Laboratories snaps six straight sessions of losses - MSN
Evercore ISI Says Abbott’s (ABT) Core Growth Drivers Are Still Intact - Insider Monkey
Hedge Fund and Insider Trading News: Ken Griffin, Bill Ackman, Mala Gaonkar, Millennium Management, Berkshire Hathaway, Abbott Laboratories (ABT), GameStop Corp (GME), and More - Insider Monkey
Abbott Eterna Spinal Cord Stimulator Lawsuit Filed Over Lead Migration, Device Malfunction - AboutLawsuits.com
AtaCor Medical Teams Up with Abbott on Defibrillator - ocbj.com
Abbott Laboratories (ABT) CEO Increases Stake with $2M Stock Purchase - GuruFocus
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Ford Robert B, Abbott Laboratories chairman, buys $2 million in ABT - Investing.com Nigeria
Ford Robert B buys Abbott shares worth $2m By Investing.com - Investing.com Nigeria
Mutual of America Capital Management LLC Sells 10,889 Shares of Abbott Laboratories $ABT - MarketBeat
3 Reasons to Buy This Dividend King After Its Steep Sell-Off - The Motley Fool
Abbott TAVR leader Chris Waddell is leaving the company - MassDevice
Abbott’s Pōkeno Entry Signals Strategic Nutrition Play - en.edairynews.com
Abbott Laboratories stock faces a Monday test as ABT hovers near a 52-week low - TechStock²
A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness - simplywall.st
Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy (NYSE:ABT) - Seeking Alpha
Sawgrass Asset Management LLC Trims Stake in Abbott Laboratories $ABT - MarketBeat
Commerzbank Aktiengesellschaft FI Buys 20,825 Shares of Abbott Laboratories $ABT - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Maravai Lifesciences Holdings (MRVI) and CVRx (CVRX) - The Globe and Mail
Is Abbott's January pullback a good time to buy? - MSN
Is Abbott’s January Pullback a Good Time to Buy? - MarketBeat
Mn Services Vermogensbeheer B.V. Acquires 9,900 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Resona Asset Management Co. Ltd. - MarketBeat
Abbott Laboratories $ABT Shares Purchased by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
UniSuper Management Pty Ltd Buys 44,239 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Gibbs Wealth Management - MarketBeat
Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity - Seeking Alpha
Abbott Laboratories (ABT) Margin Compression Challenges Steady Compounder Narrative After FY 2025 Results - simplywall.st
Abbott Laboratories Analyst Cuts Price Target After Q4 Miss, Expects Sales Growth To Accelerate In H2 - Sahm
Earnings snapshot: Abbott Laboratories Q4 beats profit estimates, but misses on revenue; initiates Q1 and FY26 outlook - MSN
Abbott Laboratories (NYSE:ABT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Assessing Abbott Laboratories (ABT) Valuation After Q4 2025 Earnings Miss And Softer 2026 Guidance - Yahoo Finance
1.56%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):